Phumeetham Suwannee, Bahk Thomas J, Abd-Allah Shamel, Mathur Mudit
1Division of Pediatric Pulmonology and Critical Care, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 2Division of Pediatric Critical Care, Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA.
Pediatr Crit Care Med. 2015 Feb;16(2):e41-6. doi: 10.1097/PCC.0000000000000314.
Continuous albuterol nebulization is generally administered at 2.5-20 mg/hr at most centers. We examined the effect of high-dose (75 or 150 mg/hr) albuterol on clinical variables in children with status asthmaticus.
Retrospective analysis of inpatient medical records and prospectively collected computerized PICU respiratory therapy database.
Twenty-five-bed multidisciplinary PICU in a tertiary care children's hospital.
Children admitted to the PICU between January 2006 and December 2007 with status asthmaticus receiving high-dose continuous albuterol nebulization. (Those with cerebral palsy, cardiac pathology, and ventilator dependence were excluded.)
: Chart review for PICU length of stay, albuterol dose, duration of nebulization, occurrence of chest pain, vomiting, tremors, hypokalemia (serum potassium < 3.0 mEq/L), and cardiac arrhythmia. Maximal heart rate, lowest diastolic blood pressure, and mean arterial pressure were compared to the variables at initiation of therapy and at hospital discharge.
Forty-two patients (22 boys and 20 girls) received high-dose continuous albuterol nebulization. Twenty-three received 75 mg/hr and 19 received 150 mg/hr (3.7 mg/kg/hr [interquartile range, 2.4-5.8 mg/kg/hr]) for a duration of 22.3 hours (interquartile range, 6.6-31.7 hr). Heart rate increased and diastolic blood pressure and mean arterial pressure were significantly lower during nebulization compared to initiation of therapy or at hospital discharge (p < 0.05). No patient required fluid resuscitation or inotropic support, and one had self-limited premature ventricular contractions. Hypokalemia occurred in five of 33 patients who had serum electrolytes measured but did not require supplementation. One patient required endotracheal intubation after initiation of nebulization, and seven patients (16.7%) received noninvasive ventilation. PICU length of stay was 2.3 ± 1.7 days; there were no deaths.
High-dose continuous albuterol nebulization is associated with a low rate of subsequent mechanical ventilation and fairly short PICU length of stay without significant toxicity. Prospective studies comparing conventional and high-dose albuterol nebulization are needed to determine the optimum dose providing maximum efficacy with the least adverse effects.
在大多数中心,持续雾化吸入沙丁胺醇的剂量一般为2.5 - 20毫克/小时。我们研究了高剂量(75或150毫克/小时)沙丁胺醇对哮喘持续状态患儿临床指标的影响。
对住院病历进行回顾性分析,并前瞻性收集计算机化的儿科重症监护病房(PICU)呼吸治疗数据库。
一家三级儿童专科医院中拥有25张床位的多学科PICU。
2006年1月至2007年12月期间入住PICU且接受高剂量持续雾化吸入沙丁胺醇治疗的哮喘持续状态患儿。(排除患有脑瘫、心脏疾病和依赖呼吸机的患儿。)
查阅病历,记录PICU住院时间、沙丁胺醇剂量、雾化持续时间、胸痛、呕吐、震颤、低钾血症(血清钾<3.0毫当量/升)和心律失常的发生情况。将最大心率、最低舒张压和平均动脉压与治疗开始时及出院时的指标进行比较。
42例患者(22例男孩和20例女孩)接受了高剂量持续雾化吸入沙丁胺醇治疗。23例接受75毫克/小时,19例接受150毫克/小时(3.7毫克/千克/小时[四分位间距,2.4 - 5.8毫克/千克/小时]),持续时间为22.3小时(四分位间距,6.6 - 31.7小时)。与治疗开始时或出院时相比,雾化期间心率升高,舒张压和平均动脉压显著降低(p<0.05)。没有患者需要液体复苏或使用血管活性药物支持,1例出现自限性室性早搏。33例检测血清电解质的患者中有5例发生低钾血症,但无需补充钾。1例患者在雾化开始后需要气管插管,7例患者(16.7%)接受了无创通气。PICU住院时间为2.3±1.7天;无死亡病例。
高剂量持续雾化吸入沙丁胺醇与后续机械通气率低及PICU住院时间较短相关,且无明显毒性。需要进行前瞻性研究比较传统剂量和高剂量沙丁胺醇雾化吸入,以确定能提供最大疗效且不良反应最小的最佳剂量。